Glycine Protects H9C2 Cardiomyocytes from High Glucose- and Hypoxia/Reoxygenation-Induced Injury via Inhibiting PKCβ 2 Activation and Improving Mitochondrial Quality

Journal of Diabetes Research
Yuan ZhangShaoqing Lei

Abstract

Patients with diabetes are more vulnerable to myocardial ischemia reperfusion injury (IRI), which is involved in PKCβ2 activation and mitochondrial dysfunction. Glycine has been documented as a cytoprotective agent to attenuate diabetes-related abnormalities and reduce myocardial IRI, but the underlying mechanisms are still unclear. We determined whether glycine could attenuate high glucose- (HG-) and hypoxia/reoxygenation- (H/R-) induced injury by inhibiting PKCβ2 activation and improving mitochondrial quality in cultured H9C2 cells. H9C2 cells were either exposed to low glucose (LG) or HG conditions with or without treatment of glycine or CGP53353 (a selective inhibitor of PKCβ2) for 48 h, then subjected to 4 h of hypoxia followed by 2 h of reoxygenation (H/R). Cell viability, lactate dehydrogenase (LDH) release, mitochondrial membrane potential (MMP), superoxide dismutase (SOD) activity, and malondialdehyde (MDA) concentration were detected using corresponding commercial kits. Mitochondrial quality control-related proteins (LC-3II, Mfn-2, and Cyt-C) and PKCβ2 activation were detected by Western blot. HG stimulation significantly decreased cell viability and SOD activity and increased LDH release, MDA production, and PKCβ2 ac...Continue Reading

References

Jan 21, 2009·Cellular and Molecular Life Sciences : CMLS·G LinK M MacLeod
Nov 26, 2009·Expert Opinion on Pharmacotherapy·Ronald P Danis, Matthew J Sheetz
May 1, 2010·Circulation Research·Pedro Geraldes, George L King
Feb 22, 2012·Interactive Cardiovascular and Thoracic Surgery·Sebastian-Patrick SommerRainer G Leyh
Nov 22, 2012·Best Practice & Research. Clinical Endocrinology & Metabolism·Sheila CollinsEinav Yehuda-Shnaidman
Dec 26, 2012·The Journal of Biological Chemistry·Changhong LiAli Naji
Apr 5, 2013·Journal of Biomedical Research·Xiaozheng ZhongQi Chen
Mar 13, 2014·American Journal of Physiology. Lung Cellular and Molecular Physiology·Bharathi AravamudanY S Prakash
Oct 22, 2014·Open Heart·Mark F McCarty, James J DiNicolantonio
Nov 19, 2014·Molecular Genetics and Metabolism Reports·Shaohua ChangThomas N Tulenko
Oct 29, 2015·BioMed Research International·Tingyang ZhouLi Zuo
Oct 30, 2015·International Journal of Molecular Sciences·Yosuke KayamaPhilip S Tsao
Jan 8, 2016·Journal of Molecular and Cellular Cardiology·Qiangrong Liang, Satoru Kobayashi
Feb 20, 2016·Experimental and Therapeutic Medicine·Guang-Xing MengYi-Jun Wang
Sep 24, 2016·American Journal of Physiology. Gastrointestinal and Liver Physiology·Shiori TakashimaSumio Watanabe
Mar 17, 2017·Oxidative Medicine and Cellular Longevity·Dajun ZhaoLifang Yang
Mar 28, 2017·Biochimica Et Biophysica Acta. Molecular Cell Research·Jinliang NanJian'an Wang
Apr 13, 2017·Molecular Neurobiology·Anthony R AnzellThomas H Sanderson

❮ Previous
Next ❯

Citations

Oct 31, 2018·Molecular & Cellular Proteomics : MCP·Etna AbadMatilde E Lleonart
Aug 2, 2019·Journal of Cellular and Molecular Medicine·Maria Consiglia TrottaGorizio Pieretti

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass
MDA
Infrared Imaging

Software Mentioned

Odyssey Application
GraphPad Prism
GraphPad

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.